Can Celera Do It Again?

See allHide authors and affiliations

Science  24 Mar 2000:
Vol. 287, Issue 5461, pp. 2136-2138
DOI: 10.1126/science.287.5461.2136

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The upstart Celera Genomics of Rockville, Maryland, is set to embark on an ambitious new effort to move beyond the human genome to conquer the next frontier: "proteomics," the effort to identify all the proteins expressed in an organism and then track their ebb and flow, a crucial step in developing novel drugs and tailoring medical care to the genetic makeup of individuals. To pay for the new initiative, Celera raised $944 million in a stock offering earlier this month, much of which will be devoted to proteomics. But Celera faces a huge challenge and some stiff competition from companies already in the field.